Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.

Morrison CD, Allington TM, Thompson CL, Gilmore HL, Chang JC, Keri RA, Schiemann WP.

Oncotarget. 2016 Nov 8;7(45):72777-72794. doi: 10.18632/oncotarget.11909.

2.

Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.

Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, Schischmanoff O.

J Cell Mol Med. 2016 Oct;20(10):1956-65. doi: 10.1111/jcmm.12887. Epub 2016 Jul 27.

3.

NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.

Li LS, Reddy S, Lin ZH, Liu S, Park H, Chun SG, Bornmann WG, Thibodeaux J, Yan J, Chakrabarti G, Xie XJ, Sumer BD, Boothman DA, Yordy JS.

Mol Cancer Ther. 2016 Jul;15(7):1757-67. doi: 10.1158/1535-7163.MCT-15-0765. Epub 2016 Apr 12.

PMID:
27196777
4.

The Kub5-Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair.

Patidar PL, Motea EA, Fattah FJ, Zhou Y, Morales JC, Xie Y, Garner HR, Boothman DA.

Nucleic Acids Res. 2016 Feb 29;44(4):1718-31. doi: 10.1093/nar/gkv1492. Epub 2016 Jan 26.

5.

DNA mismatch repair and the DNA damage response.

Li Z, Pearlman AH, Hsieh P.

DNA Repair (Amst). 2016 Feb;38:94-101. doi: 10.1016/j.dnarep.2015.11.019. Epub 2015 Dec 2. Review.

6.

DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells.

Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, Saini S, Hirata H, Deng G, Gill A, Wong DK, Shiina H, Nonomura N, Dahiya R, Tanaka Y.

Oncotarget. 2014 Nov 30;5(22):11297-307.

7.

Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.

Yong KJ, Milenic DE, Baidoo KE, Kim YS, Brechbiel MW.

Cancer Med. 2013 Oct;2(5):646-53. doi: 10.1002/cam4.132. Epub 2013 Sep 19.

8.

Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.

Klokov D, Leskov K, Araki S, Zou Y, Goetz EM, Luo X, Willson D, Boothman DA.

Oncogene. 2013 Jan 24;32(4):479-90. doi: 10.1038/onc.2012.64. Epub 2012 Mar 5.

9.

Detection of early Abl kinase activation after ionizing radiation by using a peptide biosensor.

Tang J, Wang JY, Parker LL.

Chembiochem. 2012 Mar 19;13(5):665-73. doi: 10.1002/cbic.201100763. Epub 2012 Feb 14.

10.

p50 (NF-κB1) is an effector protein in the cytotoxic response to DNA methylation damage.

Schmitt AM, Crawley CD, Kang S, Raleigh DR, Yu X, Wahlstrom JS, Voce DJ, Darga TE, Weichselbaum RR, Yamini B.

Mol Cell. 2011 Dec 9;44(5):785-96. doi: 10.1016/j.molcel.2011.09.026.

11.

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.

Li LS, Bey EA, Dong Y, Meng J, Patra B, Yan J, Xie XJ, Brekken RA, Barnett CC, Bornmann WG, Gao J, Boothman DA.

Clin Cancer Res. 2011 Jan 15;17(2):275-85. doi: 10.1158/1078-0432.CCR-10-1983. Epub 2011 Jan 11. Erratum in: Clin Cancer Res. 2011 Mar 1;17(5):1210-1.

12.

DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer.

Dong X, Li Y, Hess KR, Abbruzzese JL, Li D.

Oncologist. 2011;16(1):61-70. doi: 10.1634/theoncologist.2010-0127. Epub 2011 Jan 6.

13.

The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.

Allington TM, Schiemann WP.

Cells Tissues Organs. 2011;193(1-2):98-113. doi: 10.1159/000320163. Epub 2010 Nov 3. Review.

14.

Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.

Zhou X, Münger K.

Cancer Res. 2010 Nov 15;70(22):9434-43. doi: 10.1158/0008-5472.CAN-10-1960. Epub 2010 Oct 5.

15.

Involvement of the beta clamp in methyl-directed mismatch repair in vitro.

Pluciennik A, Burdett V, Lukianova O, O'Donnell M, Modrich P.

J Biol Chem. 2009 Nov 20;284(47):32782-91. doi: 10.1074/jbc.M109.054528. Epub 2009 Sep 25.

16.

DNA mismatch repair (MMR)-dependent 5-fluorouracil cytotoxicity and the potential for new therapeutic targets.

Li LS, Morales JC, Veigl M, Sedwick D, Greer S, Meyers M, Wagner M, Fishel R, Boothman DA.

Br J Pharmacol. 2009 Oct;158(3):679-92. doi: 10.1111/j.1476-5381.2009.00423.x. Epub 2009 Sep 23. Review.

17.

MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine.

Sun G, Jin S, Baskaran R.

Exp Cell Res. 2009 Nov 1;315(18):3163-75. doi: 10.1016/j.yexcr.2009.09.010. Epub 2009 Sep 17.

18.

Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors.

Allington TM, Galliher-Beckley AJ, Schiemann WP.

FASEB J. 2009 Dec;23(12):4231-43. doi: 10.1096/fj.09-138412. Epub 2009 Aug 18.

19.

Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling.

Topping RP, Wilkinson JC, Scarpinato KD.

J Biol Chem. 2009 May 22;284(21):14029-39. doi: 10.1074/jbc.M809303200. Epub 2009 Mar 13.

20.

Role of c-Abl kinase in DNA mismatch repair-dependent G2 cell cycle checkpoint arrest responses.

Wagner MW, Li LS, Morales JC, Galindo CL, Garner HR, Bornmann WG, Boothman DA.

J Biol Chem. 2008 Aug 1;283(31):21382-93. doi: 10.1074/jbc.M709953200. Epub 2008 May 14.

Supplemental Content

Support Center